Conditions: Central Nervous System Tumors
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 8
Healthy volunteers: no

Brief summary:
Independently, both lenalidomide and vorinostat have shown promising activity in pediatric central nervous system (CNS) tumors. These are both agents that are not typically part of first-line studies, although both agents are of serious interest and are currently in clinical trials for further investigation. This study is to evaluate the combination of lenalidomide and vorinostat in high grade or progressive central nervous system tumors in children.

Detailed description:
Brain tumors are the second most common cause of cancer in pediatrics and the leading cause of cancer death in children. For children with relapsed, refractory, or recurrent brain tumors, new agents in new combinations are needed. This study is a phase I study designed to provide an objective observation of toxicity and establish a maximum tolerated dose of this combination. In addition, this study will observe the response of children with relapsed or refractory central nervous system tumors. Lenalidomide will be dosed orally once daily days 1-21 consecutive days of a 28 day cycle. Vorinostat will be dosed orally once daily days 1-7 and 15-21 of a 28-day cycle.Doses will be escalated according to standard phase 1 dose escalation criteria. In the absence of treatment delays due to adverse event(s), treatment may continue for 24 cycles.

Arms:
arm 1: 25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®) arm 2: 50 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®) arm 3: 100 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®) arm 4: 150 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®) arm 5: 150 mg/m2 Lenalidomide (Revlimid®) and 230 mg/m2 Vorinostat (Zolinza®)

Interventions: intervention 1: 25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®) intervention 2: 50 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®) intervention 3: 100 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®) intervention 4: 150 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®) intervention 5: 150 mg/m2 Lenalidomide (Revlimid®) and 230 mg/m2 Vorinostat (Zolinza®)
Intervention descriptions: intervention 1: Drug: Lenalidomide 25 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle intervention 2: Drug: Lenalidomide 50 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle intervention 3: Drug: Lenalidomide 100 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle intervention 4: Drug: Lenalidomide 150 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle intervention 5: Drug: Lenalidomide 150 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 230 mg/m2 days 1-7 and 15-21 of a 28 day cycle

Protocol document:
SAP_000.pdf: 
 
Study Protocol Title:  
A Phase 1 Study of Lenalidomide in Combination with 
Vorinostat in Pediatric Patients with High Grade or Progressive 
Central Nervous System Tumors 
 
 
 
NCT Number: 
 
 
 
 
03050450 
 
 
 
Date:    
 
 
 
 
 
 
10/05/2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
 
 
STATISTICAL CONSIDERATIONS  
 
1.1 
Study Design/Endpoints 
 
This is a single arm phase I dose escalation study, designed to determine the safety of 
lenalidomide and vorinostat when administered to children with relapsed or progressive 
central nervous system tumors.  The starting dose and schedule are indicated in the 
treatment plan section. The study will follow a standard 3+3 patient cohort escalation 
design with escalation through five dose levels. Thus, a minimum of 6 patients and a 
maximum of 20 patients will be required to establish a recommended phase II dose. At 
Johns Hopkins All Children’s Hospital, approximately 50-60 patients with brain and 
spinal cord tumors come for evaluation and treatments.  Many of these patients relapse or 
have progressive disease. We anticipate the enrollment of approximately 20 patients 
during the study period at an enrollment rate of approximately 10 subjects per year. With 
this sample size, the 80% confidence interval if two, four , six, eight and ten patients 
show responses will be (1.8%-16.8%), (5.9%-24.9%), (10.9%-32.5%),  (16.2%-39.7%) 
and (21.8%-46.6%) respectively.  
 
Statistical analysis will be conducted at the completion of the study after accrual goals 
have been met. We will describe the baseline demographic and clinical characteristics, 
adverse events and response in all patients. Continuous variables will be summarized 
using mean, standard deviations, median, maximum and minimum values. Discrete 
variables will be summarized using counts and percentages with the corresponding 95% 
confidence intervals where appropriate. Time to event variables will be analyzed using 
Kaplan Meier methods. Progression free survival (PFS) and overall survival rates and the 
corresponding confidence intervals at fixed time points will be derived from the Kaplan 
Meier estimate. PFS will be defined as the time between date of first dose of the study 
therapy and date of progression or death, whichever occurs first. Patients will be censored 
on the date of last tumor assessment if they remain alive and do not have tumor 
progression. Surviving patients who did not receive any on-treatment tumor assessment 
will be censored on the date of first dose of study medication. A window of 1 week prior 
to the PFS rate time points will be applied to account for different tumor assessments 
dates, since not all patients adhere to scheduled dates. Descriptive statistics will be used 
to summarize time to event endpoints, if Kaplan Meier methods fail to provide estimates. 
All statistical analysis will be performed using SAS software version v 9.3 (SAS 
Institute, Inc., Cary, NC) 
 
All toxicities will be graded on all patients that receive any amount of study drug.  Only 
patients who receive 12 week of therapy will be used for final analysis.  The dose 
escalation schema, definition of DLT, and endpoints are in section 5. 
 
1.2 
Sample Size/Accrual Rate 
 


 
We anticipate the enrollment of approximately 20 patients during the study period at an 
enrollment rate of approximately 10 subjects per year. 
 
1.3 
Stratification Factors 
 
The MTD determination and dose escalation are uniform per stratum.  
 
1.4 
Analysis of Secondary Endpoints 
 
Responses will be reported as a secondary endpoint.  Every report should contain all 
patients included in the study.  For the response calculation, the report should contain at 
least a section with all eligible patients.  Another section of the report may detail the 
response rate for evaluable patients only.  However, a response rate analysis based on a 
subset of patients must explain which patients were excluded and for which reasons.  It is 
preferred that 95% confidence limits are given. 
 
1.5 
Reporting and Exclusions 
 
1.5.1 
Evaluation of Toxicity 
 
All patients will be evaluable for toxicity from the time of their first treatment. 
 
1.5.2 
Evaluation of Response 
 
All patients included in the study must be assessed for response to treatment, 
even if there are major protocol treatment deviations or if they are ineligible.  
Each patient will be assigned one of the following categories:  1) complete 
response, 2) partial response, 3) stable disease, 4) progressive disease, 5) early 
death from malignant disease, 6) early death from toxicity, 7) early death 
because of other cause, or 9) unknown (not assessable, insufficient data).  [Note:  
By arbitrary convention, category 9 usually designates the “unknown” status of 
any type of data in a clinical database.] 
 
All of the patients who met the eligibility criteria (with the possible exception of 
those who received no study medication) should be included in the main analysis 
of the response rate.  Patients in response categories 4-9 should be considered to 
have a treatment failure (disease progression).  Thus, an incorrect treatment 
schedule or drug administration does not result in exclusion from the analysis of 
the response rate.  Precise definitions for categories 4-9 will be protocol specific.  
 
All conclusions should be based on all eligible patients.  Subanalyses may then 
be performed on the basis of a subset of patients, excluding those for whom 
major protocol deviations have been identified (e.g., early death due to other 
reasons, early discontinuation of treatment, major protocol violations, etc.).  
However, these sub analyses may not serve as the basis for drawing conclusions 


concerning treatment efficacy, and the reasons for excluding patients from the 
analysis should be clearly reported.  The 95% confidence intervals should also be 
provided.  


 

Prot_ICF_001.pdf: 
 
Study Protocol Title:  
A Phase 1 Study of Lenalidomide in Combination with 
Vorinostat in Pediatric Patients with High Grade or Progressive 
Central Nervous System Tumors 
 
 
 
NCT Number: 
 
 
 
 
03050450 
 
 
 
Date:    
 
 
 
 
 
 
10/05/2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


1. 
OBJECTIVES 
 
1.1 
Primary Objectives 
 
1.1.1    To conduct a phase I study to evaluate the safety and tolerability of this combination of 
chemotherapy agents. 
 
1.1.2    To determine the response of children with recurrent or refractory central nervous system 
tumors with this combination of chemotherapy agents. 
 
 
1.2 
Secondary Objectives 
 
1.2.1    To compare the response and toxicity with historical controls in prior published studies of 
patients with the same disease. 
 
1.2.2    To estimate the 2- and 5-year survival with children treated with this regimen. 
 
1.2.3    To provide safety and efficacy data to recommend further larger studies. 
 
 
 
 
2. 
PATIENT SELECTION 
2.1 
Inclusion Criteria  
2.1.1 Patients must have histologically confirmed (exception: diffuse intrinsic pontine glioma 
or optic pathway tumor) central nervous system malignancy for which standard curative 
measures do not exist or are no longer effective (i.e. patient must have received prior 
standard therapy in order to be considered eligible).  
2.1.2 Patients must have measurable disease (see section 10.1.2 for definition of measurable 
disease).  
2.1.3 Prior therapy restrictions: 
 
Patient may not have received vorinostat and lenalidomide in combination.   
 
At least 3 weeks since prior chemotherapy.   
 
At least 6 weeks from last nitrosurea.   
 
At least 6 weeks from autologous transplant.   
 
At least 3 months from bone marrow donor transplant.  
 
At least 3 weeks from focal radiation.   
 
At least 6 weeks from craniospinal radiation.  
 
Must have not received growth factors within 1 week of study entry.  
 
Must be on a stable or decreasing dose of steroids for 1 week prior.   
 
Must not be receiving any chemo, biologic, or radiation therapy.  
 
Must not be receiving enzyme inducing anticonvulsants or valproic acid. 


 
Must not be receiving pro-thrombotic agents 
2.1.4 ≥1 Age (in years) <21 
2.1.5 Karnofsky or Lansky performance status ≥50% 
2.1.6 Life expectancy of greater than 8 weeks  
2.1.7 Patients must have normal organ and marrow function as defined below: 
Absolute neutrophil count 
≥1,000/mcL 
Platelets 
≥100,000/mcL 
Pulse oximetry  
>93% 
Total bilirubin  
≤ 1.5 x upper limit of normal (ULN) 
AST(SGOT)/ALT(SGPT) 
≤2.5 × institutional upper limit of normal 
Creatinine 
within normal institutional limits OR 
Creatinine clearance  
≥60 mL/min/1.73 m2 for patients with creatinine levels 
above institutional normal. 
3.1.7 Pregnancy and breast feeding  
The effects of vorinostat and lenalidomide on the developing human fetus are unknown.  
For this reason and because agents used in this trial are known to be teratogenic, women 
of child-bearing potential must commit to complete abstinence or use TWO methods of 
birth control (one highly effective (i.e. IUD, birth control pills, injections, implants, tubal 
ligation, partner’s vasectomy), and one additional method (i.e. male condom, diaphragm, 
cervical cap) for the duration of study participation and at least 28 days after completion.  
Females of childbearing potential must agree to ongoing pregnancy testing and 
counseling every 28 days about pregnancy precautions. If a female has not had a 
menstrual period in the preceding 24 consecutive months or has had a hysterectomy, the 
two methods of birth control requirement does not apply.  Should a woman become 
pregnant or suspect she is pregnant while she or her partner is participating in this study, 
she should inform her treating physician immediately.  Men treated or enrolled on this 
protocol must agree to use condoms for the duration of study participation, and 28 days 
after completion. 
 
3.1.8 Patient or guardian ability to understand and provide written informed consent. 
 
3.1.9  Must be able to swallow lenalidomide capsules. 
 
 
2.2 
Exclusion Criteria 
 
2.2.1 Patient has not recovered from acute toxic effects of all prior therapies.  
 
2.2.2 Patients who are receiving any other investigational agents. 
 
2.2.3 History of allergic reactions attributed to compounds of similar chemical or biologic 
composition to vorinostat or lenalidomide.  
 


2.2.4 Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, 
dyspnea at rest, symptomatic congestive heart failure, history of thromboembolism 
unrelated to central line, patients with known predisposition syndrome for 
thromboembolism, patients receiving anticoagulation therapy, unstable angina pectoris, 
cardiac arrhythmia, patients receiving enzyme inducing anticonvulsants, patients 
receiving valproic acid, patients receiving antiplatelet agents (aspirin, anti-inflammatory 
drugs), or psychiatric illness/social situations that would limit compliance with study 
requirements. 
 
2.2.5 Pregnant women are excluded from this study due to the potential for teratogenic effects.  
Because there is an unknown but potential risk for adverse events in nursing infants 
secondary to treatment of the mother with these agents, breastfeeding should be 
discontinued if the mother is being treated and not resumed until 28 days after completing 
therapy.  
 
2.2.6 HIV-positive patients on combination antiretroviral therapy are ineligible because of the 
potential for pharmacokinetic interactions with these agents.  In addition, these patients 
are at increased risk of lethal infections when treated with marrow-suppressive therapy.   
 
2.4 
Inclusion of Women and Minorities 
 
Both males and females of all races and ethnic groups are eligible for this trial. 
 
3. 
TREATMENT PLAN 
 
Treatment will be administered primarily on an outpatient basis, although may be given 
inpatient based on location or status of patient.  Reported adverse events and potential 
risks are described in Section 7.  Appropriate dose modifications are described in Section 
6.  No investigational or commercial agents or therapies other than those described below 
may be administered with the intent to treat the patient's malignancy. 
 
Each cycle will begin with ANC >1000 and platelet count >100 without transfusion 
support.  At the beginning of each cycle pregnancy testing must be confirmed negative 
for females of child bearing potential and counseling regarding pregnancy risks must be 
confirmed for all patients 
 
 
 
4. STUDY SCHEMA  
 
This is a phase I study of the combination of vorinostat and lenalidomide.  
 
Cycle 
Days 
Medication 
Route 
1-7 
8-14 
15-21 
22-28 


 
 
 
 
Dose Escalation Schedule 
Dose Level 
Dose 
Lenalidomide 
mg/m2 
Vorinostat 
mg/m2 
Level 1 
25 
180 
Level 2 
50 
180 
Level 3 
100 
180 
Level 4 
150 
180 
Level 5 
150 
230 
 
 
5.  ADVERSE EVENT REPORTING 
 
All Adverse Events of any grade must be reported in routine study data submissions.  
AEs reported to the IRB in an expedited manner (i.e. adverse events meeting the IRB’s 
definition of an unanticipated problem) must also be reported in routine study data 
submissions. All relevant follow-up information concerning adverse events should be 
collected as soon as possible. 
 
 
Lenalidomide 
PO/GT/J
T 
X 
X 
X 
Rest 
Vorinostat 
PO/GT/J
T 
X 
Rest 
X 
Rest 


6. STUDY CALENDAR 
 
Baseline evaluations are to be conducted within 2 weeks prior to start of protocol therapy.  
Scans and x-rays must be done <4 weeks prior to the start of therapy.  In the event that 
the patient’s condition is deteriorating, laboratory evaluations should be repeated within 
48 hours prior to initiation of the next cycle of therapy.  
 
Timing of protocol therapy administration and response assessment studies are based on 
schedules derived from the experimental design or on established standards of care. 
Minor unavoidable departures (up to 72 hours) from protocol directed therapy and/or 
disease evaluations for valid clinical, patient and family logistical, or facility, procedure 
and/or anesthesia scheduling issues are acceptable (except where explicitly prohibited 
within the protocol). 
 
Procedure 
Pre- 
Stud
y 
Wk 
1 
Wk 
2 
Wk 
3 
Wk 
4 
Wk 
5 
Wk 
6 
Wk 
7 
Wk 
8 
Wk 
9 
Wk 
10 
Wk 
11 
Wk 
12c 
Off 
Studyd 
Informed 
consent 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lenalidomide 
 
A 
A 
A 
 
A 
A 
A 
 
A 
A 
A 
 
 
Vorinostat 
 
B 
 
B 
 
B 
 
B 
 
B 
 
B 
 
 
Demographics 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical history 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concurrent 
meds 
X 
X----------------------------------------------------------------------------X 
 
Physical exam 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
Vital signs 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
Height 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
Weight 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
Performance 
status 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
CBC w/diff, plts 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
Serum 
chemistrya 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
ECG 
X 
 
 
 
 
 
 
 
 
 
 
 
X 
x 
MRI 
brain/spinee 
X 
 
 
 
 
 
 
 
 
 
 
 
X 
 
Adverse event 
 
X-----------------------------------------------------------------------------X 
X 


evaluation 
B-HCG 
Xb 
Xb 
Xb 
Xb 
Xb 
 
 
 
Xb 
 
 
 
Xb 
 
A: Dose as assigned; administration schedule 
B:    Dose as assigned; administration schedule 
a: Albumin, alkaline phosphatase, total bilirubin, bicarbonate, BUN, calcium, chloride, 
creatinine, glucose, LDH, phosphorus, potassium, total protein, SGOT [AST], SGPT 
[ALT], sodium. 
b: Serum or urine pregnancy test (women of childbearing potential). Obtain 10-14 days prior 
to study enrollment and again within 24 hours prior to Day 1 of each cycle. Obtain weekly 
during cycle 1. Females with irregular menstruation must have a pregnancy test every 14 
days while receiving protocol therapy (including breaks in treatment). Pregnancy test is also 
required if patient misses her period or has unusual menstrual bleeding. Pregnancy testing 
must also occur at Day 28 (and at Day 14 if female has irregular menstruation) after 
lenalidomide discontinuation).   
c:     Continue pattern of measurements while on study. 
d: Off-study evaluation   
e:     As indicated based on diagnosis and tumor location.  
 
 
 


RESEARCH PARTICIPANT INFORMED CONSENT AND 
PRIVACY AUTHORIZATION FORM 
 
 
Protocol Title:  
ACH CNS 005- A Phase 1 Study of Lenalidomide in 
Combination with Vorinostat in Pediatric   Patients 
with   High Grade or Progressive Central Nervous 
System Tumors  
 
Application No.: 
IRB00085329 
 
Sponsor: 
Stacie Stapleton, M.D. 
 
Principal Investigator: Stacie Stapleton, M.D. 
 
600 5th St. South 
 
3rd Fl., Suite 302 
 
St. Petersburg, FL  33701 
 
Phone: 727-767-4176 
 
Fax: 727-767-4379 
  
1. 
What you should know about this study: 
 You are being asked to join a research study. This consent form explains the research 
study and your part in it. Please read it carefully and take as much time as you need. 
Ask your study doctor or the study team to explain any words or information that you 
do not understand. 
 You are a volunteer.  If you join the study, you can change your mind later.  There 
will be no penalty or loss of benefits if you decide to quit the study.   
 During the study, we will tell you if we learn any new information that might affect 
whether you wish to continue to participate. 
 If we think your participation in this study may affect your clinical care, information 
about your study participation will be included in your medical record, which is used 
throughout Johns Hopkins.   Doctors outside of Johns Hopkins may not have access 
to this information.  You can ask the research team to send this information to any of 
your doctors. 
 When Johns Hopkins is used in this consent form, it includes The Johns Hopkins 
University, The Johns Hopkins Hospital, Johns Hopkins Bayview Medical Center, 
Howard County General Hospital, Johns Hopkins Community Physicians, Suburban 
Hospital, Sibley Memorial Hospital and Johns Hopkins All Children’s Hospital.  
 A description of this clinical trial will be available on http://www.ClinicalTrials.gov, 
as required by U.S. Law.  This Web site will not include information that can identify 
you. At most, the Web site will include a summary of the results. You can search this 
Web site at any time.  


 If you would like to review the information for this study, or a summary of the 
results, ask the study team doctor for the ClinicalTrials.gov study registration number. 
 During this study, you will not have access to certain medical information and test 
results collected for study purposes.  If an emergency occurs while you are in the 
study, medical information needed for your treatment can be made available to your 
study physician and other physicians who treat you.  When the study is completed, all 
the information in your medical record will be available to you. 
 If children and adults can join this study, the word “you” in this consent form will 
refer to both you and your child.  
 The person being asked to be in this research study may not be able to give consent to 
be in this study. You are therefore being asked to give permission for this person to 
be in the study as his/her decision maker. 
 
2. 
Why is this research being done? 
This research is being done to determine the safety and effectiveness of using 
lenalidomide and vorinostat. Independently, both lenalidomide and vorinostat have 
shown promising activity in pediatric central nervous system tumors. This study is to 
evaluate the safety of lenalidomide and vorinostat in central nervous system (brain and 
spine) tumors in children.  
 
Lenalidomide is approved by the Food and Drug Administration (FDA) for the treatment 
in adults of relapsed mantle cell lymphoma, multiple myeloma and myelodysplastic 
syndrome (a bone marrow disorder).  
 
Vorinostat is approved by the FDA for the treatment in adults of primary cutaneous T-
cell lymphoma.  
        
The use of lenalidomide and vorinostat together in this research study is investigational. 
The word “investigational” means that lenalidomide and vorinostat are not approved for 
marketing by the FDA to treat pediatric central nervous system (CNS) disorders.  
 
The purpose of this study is to determine the safety of using these two drugs together.  
 
People with recurrent or relapsed or refractory CNS tumors may join.   
 
How many people will be in this study? 
This study will be a multi-institutional study. We anticipate enrolling up to 20 
participants on this study. About 12 people will take part at Johns Hopkins All 
Children’s. 
 
3. 
What will happen if you join this study? 
If you agree to be in this study, we will ask you to follow a study drug plan. The plan will 
consist of lenalidomide and vorinostat given by mouth (PO). Lenalidomide capsules must 
be swallowed whole.  Vorinostat may be swallowed whole, or a suspension is available, 
or may be given via a gastrostomy tube (g-tube) or jejunostomy tube (j-tube) 
.Lenalidomide will be given on days 1-21 of a 28 day cycle. Vorinostat will be given on 


days 1-7 and days 15-21 of the same 28 day cycle.  
 
 
 
A diagram of study drugs is below: 
 
 
 
Please note: 
Lenalidomide should be taken without food if possible.   
Vorinostat should be taken with food if possible. 
 
 
You will need to have the following exams, tests or procedures to find out if you can be 
in the study and to check how you are doing during taking the study drugs. These exams, 
tests or procedures are part of regular cancer care and may be done even if you do not 
join the study. If you have had some of them recently, they may not need to be repeated. 
This will be up to your study doctor.  
 
 Physical exam every 2 weeks 
 Blood tests every 2 weeks 
 Electrocardiogram every 3 cycles (every 12 weeks) to evaluate your heart’s rhythm 
 MRI scans to determine whether your tumor is responding to study drug every 3 
cycles (every 12 weeks) 
 If you are a female of childbearing potential (capable of getting pregnant), you will 
need a serum (blood) or urine pregnancy test 10-14 days prior to study enrollment and 
again within 24 hours prior to Day 1 of each cycle. If you are a female with irregular 
periods, you will have a pregnancy test every 14 days while on the study. Pregnancy 
tests may be performed if you are a female who misses her period or has unusual 
menstrual bleeding. Pregnancy testing will also occur at Day 28 (and at Day 14 if 
irregular periods) after stopping lenalidomide. 
 Counseling about pregnancy prevention will occur prior to every cycle   
 
How long will you be in the study? 
You may receive study drugs for up to 2 years if you are responding well and tolerating 
the medications.  
 
4. 
What are the risks or discomforts of the study? 
 
Risks and side effects related to lenalidomide include those which are: 
Cycle 
Days 
Medication 
Route 
1-7 
8-14 
15-21 
22-28 
Lenalidomide 
PO/GT/JT 
X 
X 
X 
Rest 
Vorinostat 
PO/GT/JT 
X 
Rest 
X 
Rest 
COMMON, SOME MAY BE SERIOUS   
In 100 people receiving lenalidomide, more than 20 and up to 100 may have: 


 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Anemia which may require blood transfusion 
 Constipation 
 Diarrhea 
 Tiredness 
 Bruising, bleeding 
 
OCCASIONAL, SOME MAY BE SERIOUS   
In 100 people receiving lenalidomide, from 4 to 20 may have: 
 Nausea, vomiting 
 Chills, fever 
 Swelling of arms, legs 
 Infection, especially when white blood cell count is low 
 Weight loss, loss of appetite 
 Pain  
 Muscle spasms 
 Dizziness, headache 
 Difficulty sleeping 
 Cough, shortness of breath 
 Increased sweating 
 Itching, rash 
 Sores on the skin 
 Blood clot which may cause swelling, pain, shortness of breath 
 Change in mood (e.g. depression) 
 Change in mental status 
 Change in neurologic function 
 Thoughts of suicide 
 Seizures 
 Irregular heartbeat 


 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RARE, AND SERIOUS 
In 100 people receiving lenalidomide, 3 or fewer may have: 
 Allergic reaction which may cause rash, low blood pressure, wheezing, shortness of 
breath,  swelling of the face or throat and may cause death 
 Damage to organs in the body when immune cells attack host organs which may cause 
yellowing of eyes and skin, itchy dry skin, or muscle weakness 
 Kidney damage which may require dialysis or may cause swelling 
 Cancer of bone marrow caused by chemotherapy 
 
 Damage to organs which may cause infection, bleeding, changes in thinking, or may 
require transfusions 
 Increased tumor size 
 A new cancer resulting from treatment of earlier cancer 
 
 Severe skin rash with blisters and can involve inside of mouth and other parts of the 
body  
 Heart attack 
 Liver damage which may cause yellowing of eyes and skin, swelling, and may cause 
death 
 Stroke which may cause paralysis weakness 
 Difficulty stimulating enough stem cells in the bloodstream for future transplant 
 


 
On rare occasions a second cancer arises after patients have undergone cancer 
therapy, including therapy using chemotherapeutic agents.  Recently, in clinical trials 
of patients with newly diagnosed multiple myeloma (a tumor with cells that are 
usually found in bone marrow), a higher number of second cancers has been reported 
in patients treated with high doses of chemotherapy (induction therapy) and/or stem 
cell transplant followed by prolonged (maintenance) lenalidomide therapy compared 
to those who received induction therapy and/or transplant without maintenance 
lenalidomide.   
 
We do not know at this time whether prolonged lenalidomide therapy in this clinical setting 
actually increases the risk of second primary cancers.   
 
No increase in second primary cancers has been observed in patients receiving 
lenalidomide therapy who have relapsed multiple myeloma or other types of cancer.   
 
We will be carefully monitoring these events (second primary cancers) in on-going studies 
of lenalidomide therapy and will inform you if there are any changes.   
We want you to be aware of this possibility and to continue to follow standard medical 
advice for prevention and early detection of other cancers during and after your study 
drugs.  
 
Please Note: If capsules cannot be swallowed whole, they may be opened and sprinkled on 
applesauce.  Proper handling must be used to avoid exposure to this drug. A handout will 
be given to you to describe this process. 
 
Participants should not donate blood during the study or for 28 days after stopping 
lenalidomide. 
 
Risks and side effects related to vorinostat include those which are: 
 
COMMON, SOME MAY BE SERIOUS   
In 100 people receiving vorinostat, more than 20 and up to 100 may have: 
 Anemia which may require blood transfusion 
 Diarrhea, nausea, vomiting 
 Tiredness 
 Bruising, bleeding 
 Loss of appetite 
 Changes in taste 
 
OCCASIONAL, SOME MAY BE SERIOUS   
In 100 people receiving vorinostat, from 4 to 20 may have: 
 Belly pain 
 Constipation, heartburn 
 Dry mouth 
 Fever 


 Infection, especially when white blood cell count is low 
 Weight loss 
 Dehydration 
 Muscle spasms or weakness 
 Dizziness 
 Cough, shortness of breath 
 Hair loss 
 
RARE, AND SERIOUS 
In 100 people receiving vorinostat, 3 or fewer may have: 
 Damage to the skin 
 Formation of clot in a blood vessel 
 Elevated blood sugar levels 
 
Some drugs or supplements may interact with your study drug plan. Talk to your doctor, 
pharmacist, or study team before starting any new prescription or over-the-counter 
drugs, herbals, or supplements and before making a significant change in your diet. 
Supplements may come in many forms, such as teas, drinks, juices, liquids, drops, 
capsules, pills, or dried herbs. All forms should be avoided. 
 
In addition to the risks described above, there may be unknown risks, or risks that we did 
not anticipate, associated with being in this study. You will be monitored for side effects 
and supportive care will be given if needed.  
 
5. 
Are there risks related to pregnancy? 
Lenalidomide is related to thalidomide. Thalidomide is known to cause severe life-
threatening human birth defects. Findings from a monkey study indicate that 
lenalidomide caused birth defects in the babies of female monkeys who received the drug 
during pregnancy. If lenalidomide is taken during pregnancy, it may cause birth defects 
or death to any unborn baby. You have been informed that the risk of birth defects is 
unknown.  
 
Women must not become pregnant while taking lenalidomide. If you or your partner can 
get pregnant, it is important for you to use 2 forms of birth control or not have sex before 
starting lenalidomide, while on this study, and for 4 weeks after you stop being treated on 
this study. Check with your study doctor about what kind of birth control methods to use.  
 
Some birth control methods might not be approved for use in this study. Women should 
not breastfeed a baby while on this study or for 28 days after study drug is over.  
 
Men should not father a baby while on this study. When taking lenalidomide, the drug is 
present in semen of healthy men at very low levels for three days after stopping the drug.  
For patients who may not be able to get rid of the drug, such as people with kidney 
problems, lenalidomide may be present for more than three days. To be safe, all men 
should use condoms when engaging in sexual intercourse while taking lenalidomide, 
when temporarily stopping lenalidomide, and for 28 days after permanently stopping 


lenalidomide if their partner is either pregnant or able to have children.  Men should not 
donate sperm or semen while on this study or for 28 days after study drug is over.  
 
The effects of vorinostat and lenalidomide on the developing human fetus are unknown. 
For this reason and because agents used in this trial are known to be teratogenic, women 
of child-bearing potential must commit to complete abstinence or use TWO methods of 
birth control (one highly effective (i.e. IUD, birth control pills, injections, implants, tubal 
ligation, partner’s vasectomy), and one additional method (i.e. male condom, diaphragm, 
cervical cap) for the duration of study participation and at least 28 days after completion. 
Females of childbearing potential must agree to ongoing pregnancy testing and 
counseling every 28 days about pregnancy precautions. If a female has not had a 
menstrual period in the preceding 24 consecutive months or has had a hysterectomy, the 
two methods of birth control requirement does not apply. Should a woman become 
pregnant or suspect she is pregnant while she or her partner is participating in this study, 
she should inform her treating physician immediately. Men treated or enrolled on this 
protocol must agree to use latex condoms for the duration of study participation, and 28 
days after completion. 
 
This research may hurt an embryo or fetus in ways we do not currently know.  
 
 
 
6. 
Are there benefits to being in the study? 
Benefits include possible improved tumor control and improved clinical symptoms. We 
do not know that the information from this study will help doctors learn more about 
treating central nervous system tumors. This information could help future cancer 
patients.  
 
7. 
What are your options if you do not want to be in the study? 
If you decide not to join this study, other options are available.  You do not have to join 
this study to get    treatment.  Other treatments include regimens that would be 
individualized based on your prior treatment and diagnosis. You do not have to join this 
study.  If you do not join, your care at Johns Hopkins will not be affected. 
 
8. 
Will it cost you anything to be in this study?   
You will receive a separate Insurance and Research Participant Financial Responsibility 
Information Sheet (Sheet).  
 
This Sheet will give you the following information: 
 
 The procedures, tests, drugs or devices that are part of this research and that will 
be paid for by the study (no cost to you).   
 
 The procedures, tests, drugs or devices that will be billed to you and/or your 
health insurer.  If you have health insurance, you will be responsible for any co-
pays or deductibles not covered by your insurance.  


 
9. 
Will you be paid if you join this study? 
No, you will not be paid if you join this study. 
 
10. 
Can you leave the study early? 
You can decide to stop at any time. Tell the study doctor if you are thinking about 
stopping or decide to stop. He or she will tell you how to stop safely.  
 
It is important to tell the study doctor if you are thinking about stopping so any risks from 
the therapy can be evaluated by your doctor. Another reason to tell your doctor that you 
are thinking about stopping is to discuss what follow-up care and testing could be most 
helpful for you. 
 
If you leave the study early, Johns Hopkins may use or give out your health information 
that it has already collected if the information is needed for this study or any follow-up 
activities.  
 
11. 
Why might we take you out of the study early?  
You may be taken out of the study if: 
 
 Staying in the study would be harmful 
 You need treatment not allowed in the study 
 You fail to follow instructions 
 You become pregnant 
 The study is cancelled 
 There may be other reasons to take you out of the study that we do not know at 
this time 
 
The study doctor may stop you from taking part in this study at any time if he/she 
believes it is in your best interest, if you do not follow the study rules, or if the study is 
stopped.  
 
If you are taken out of the study early, Johns Hopkins may use or give out your health 
information that it has already collected if the information is needed for this study or any 
follow-up activities. 
 
12. 
How will your privacy be protected?  
We have rules to protect information about you.  Federal and state laws and the federal 
medical Privacy Rule also protect your privacy.  By signing this form you provide your 
permission, called your “authorization,” for the use and disclosure of information 
protected by the Privacy Rule. 
 
The research team working on the study will collect information about you.  This 
includes things learned from the procedures described in this consent form.   
They may also collect other information including your name, address, date of birth, and 
information from your medical records (which may include information about HIV 


status, drug, alcohol or STD treatment, genetic test results, or mental health treatment). 
 
The research team will know your identity and that you are in the research study.  Other 
people at Johns Hopkins, particularly your doctors, may also see or give out your 
information. We make this information available to your doctors for your safety.    
 
People outside of Johns Hopkins may need to see or receive your information for this 
study.  Examples include government agencies (such as the Food and Drug 
Administration), safety monitors, other sites in the study and companies that sponsor the 
study.  
 
We cannot do this study without your authorization to use and give out your information.  
You do not have to give us this authorization.  If you do not, then you may not join this 
study. 
 
We will use and disclose your information only as described in this form and in our 
Notice of Privacy Practices; however, people outside Johns Hopkins who receive your 
information may not be covered by this promise or by the federal Privacy Rule.  We try 
to make sure that everyone who needs to see your information keeps it confidential – but 
we cannot guarantee that your information will not be re-disclosed. 
 
The use and disclosure of your information has no time limit. You may revoke (cancel) 
your permission to use and disclose your information at any time by notifying the 
Principal Investigator of this study by phone or in writing.  If you contact the Principal 
Investigator by phone, you must follow-up with a written request that includes the study 
number and your contact information.  The Principal Investigator’s name, address, phone 
and fax information are on page one of this consent form.  
 
If you do cancel your authorization to use and disclose your information, your part in this 
study will end and no further information about you will be collected. Your revocation 
(cancellation) would not affect information already collected in the study, or information 
we disclosed before you wrote to the Principal Investigator to cancel your authorization. 
 
13. 
What treatment costs will be paid if you are injured in this study?  
Johns Hopkins does not have a program to pay you if you are hurt or have other bad 
results from being in the study.  However, medical care at Johns Hopkins is open to you 
as it is to all sick or injured people.   
 
The costs for any treatment or hospital care you receive as the result of a study-related 
injury that are not covered by a health insurer will be billed to you. 
 
By signing this form you will not give up any rights you have to seek compensation for 
injury.  
 
14. 
What other things should you know about this research study? 
a. What is the Institutional Review Board (IRB) and how does it protect you?  


The Johns Hopkins Medicine IRB is made up of: 
 Doctors 
 Nurses 
 Ethicists 
 Non-scientists 
 and people from the local community.  
 
The IRB reviews human research studies. It protects the rights and welfare of the 
people taking part in those studies.   
You may contact the IRB if you have questions about your rights as a participant or if 
you think you have not been treated fairly.  The IRB office number is 727-767-4275. 
You may also call this number for other questions, concerns or complaints about the 
research. 
 
When the Johns Hopkins School of Medicine Institutional Review Board (IRB) 
reviews a study at another site, that site (institution) is solely responsible for the safe 
conduct of the study and for following the protocol approved by the Johns Hopkins 
IRB.   
 
b. What do you do if you have questions about the study?    
Call the principal investigator, Dr. Stacie Stapleton at 727-767-4176. If you wish, you 
may contact the principal investigator by letter or by fax.  The address and fax 
number are on page one of this consent form. If you cannot reach the principal 
investigator or wish to talk to someone else, call the IRB office at 727-767-4275.   
 
c. What should you do if you are injured or ill as a result of being in this study?  
If you think you are injured or ill because of this study, call Dr. Stacie Stapleton at 
727-767-4176 during regular office hours.  
 
If you have an urgent medical problem related to your taking part in this study, call 
the oncology office at 727-767-4176 during regular office hours and the on-call 
oncologist at 727-767-4176 after hours and on weekends.  
  
d. What happens to Data that is collected in the study?  
Johns Hopkins and our research partners work to understand and cure diseases. The 
data you provide is important to this effort. 
 
If you join this study, you should understand that you will not own your data, and 
should researchers use your data to create a new product or idea, you will not benefit 
financially.  
 
15. 
Assent Statement 
This research study has been explained to my child in my presence in language my child 
can understand.  He/she has been encouraged to ask questions about the study now and at 
any time in the future. 
 


16. 
What does your signature on this consent form mean?  
Your signature on this form means that: You understand the information given to you in this 
form, you accept the provisions in the form and you agree to join the study. You will not give up 
any legal rights by signing this consent form.  
 
WE WILL GIVE YOU A COPY OF THIS SIGNED AND DATED 
CONSENT FORM 
 
 
________________________________________________________________________________________________________
________________ 
Signature of Participant                                                                           (Print Name)                                              
 
Date/Time  
 
 
______________________________________________________________________________
______________________________ 
Signature of Person Obtaining Consent                                                  (Print Name)                                              
 
 
Date/Time 
 
 
______________________________________________________________________________
______________________________ 
Signature of Legally Authorized Representative (LAR)                       (Print Name)                                                
 
Date/Time    
For ADULTS NOT CAPABLE of GIVING CONSENT (Persons from the following 
categories in order of 
priority may be a Legally Authorized Representative: Health Care Agent; Legal Guardian; 
Spouse; Adult child;  
Parent; Adult sibling; Friend or other relative)  
 
______________________________________________________________________________
______________________________ 
Relationship of LAR to Participant (indicate why the LAR is authorized                                                        
 
 
Date/Time 
to act as a surrogate health care decision-maker under  state or applicable local law) 
 
 
______________________________________________________________________________
______________________________ 
Signature of Parent                                                                                 (Print Name)                                        
 
 
Date/Time 
 
 
______________________________________________________________________________


______________________________ 
Signature of Legally Authorized Representative (LAR)                        (Print Name) 
 
Date/Time  
For CHILD PARTICIPANT 
 
______________________________________________________________________________
____________________________ 
Description of LAR’s authority under state or applicable local law to act as surrogate health care                          
Date/Time            decision-maker for child research participant (for example, Legal Guardian, 
court-ordered representative) 
 
______________________________________________________________________________
______________________________ 
Signature of Child Participant (optional unless IRB required)              (Print Name)                                       
 
 
Date/Time 
 
 
______________________________________________________________________________
______________________________ 
Signature of Witness to Consent Procedures                                         (Print Name) 
 
Date/Time 
 
 
 
I have received the separate Insurance and Research Participant Financial Responsibility 
Information Sheet.   
 
______________________________________________________________________________
_____________________________ 
Signature of Participant, LAR or Parent/Guardian                               (Print Name)                                                 
Date/Time 
 
NOTE: A COPY OF THE SIGNED, DATED CONSENT FORM MUST BE KEPT BY THE PRINCIPAL 
INVESTIGATOR; A COPY MUST BE GIVEN TO THE PARTICIPANT; IF YOU ARE USING EPIC FOR THIS 
STUDY A COPY MUST BE FAXED TO 410-367-7382; IF YOU ARE NOT USING EPIC A COPY MUST BE PLACED 
IN THE PARTICIPANT’S MEDICAL RECORD (UNLESS NO MEDICAL RECORD EXISTS OR WILL BE 
CREATED).  
 
ONLY CONSENT FORMS THAT INCLUDE THE JOHNS HOPKINS MEDICINE LOGO CAN BE USED TO 
OBTAIN THE CONSENT OF RESEARCH PARTICIPANTS.